Activity of interferon-α in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma

Annals of Oncology

Volumn 11, Issue 3, 2000, Pages 359-361

  Armitage, J O ^a   Coiffier, B ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Interferon ; Non Hodgkin's lymphoma

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG ACTIVITY; DRUG EFFECT; FOLLICULAR LYMPHOMA; HUMAN; MALE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE ACTIVATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FATAL OUTCOME; HUMANS; INTERFERON-ALPHA; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SKIN;

EID: 0033993704     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008384506227     Document Type: Article

References (18)

1. Coiffier B. Recombinant interferon-α in the treatment of lymphoma patients. Rev Clin Exp Hematol 1998; 6: 36-54.
2. Smalley RV, Anderson SA, Tuttle RL et al. A randomized comparison of two doses of human lymphoblastoid interferon-α in hairy cell leukemia. Blood 1991; 78: 3133-41.
3. Solal-Celigny P, Lepage E, Brousse N et al. Recombinant interferon-α2b combined with a regimen containing doxorubicin in advanced follicular lymphoma. N Engl J Med 1993; 329: 1608-14.
4. Bunn PA, Hoffman SJ, Norris D et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121: 592-602.
5. Jumbou O, N'Guyen JM, Tessier MH et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-α. Br J Dermatol 1999; 140: 427-31.
6. Haley HR, Davis DA, Sams WM. Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis. J Am Acad Dermatol 1999; 41: 880-3.
7. Pettitt AR, Zuzel M, Cawley JC. Hairy-cell leukaemia: Biology and management. Br J Haematol 1999; 106: 2-8.
8. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood 1999; 94: 1517-36.
9. San Miguel JF, Creixenti JB, Garcia-Sanz R. Treatment of multiple myeloma. Haematologica 1999; 84: 36-58.
10. Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-α as treatment for metastatic melanoma and renal-cell carcinoma: An overview of randomized trials. J Immunother 1999; 22: 145-54.
11. Foon KA, Sherwin S, Abrams P. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311: 1148-52.
12. Horning SJ, Merigan T, Krown S. Human interferon-α in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. Cancer 1985; 56: 1305-10.
13. Leavitt RD, Ratanatharathorn V, Ozer H et al. Interferon-α2b in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1987; 14 (Suppl 2): 18-23.
14. Harris NL, Jaffe ES, Diebold J et al. World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.
15. Kurie JM, Hong WK. Retinoids as antitumor agents: A new age of biological therapy. Cancer J Sci Am 1999; 5: 150-1.
16. Merigan TL, Sikorak K, Breeden JH et al. Preliminary observations on the effect of human leukocyte interferon in non-Hodgin's lymphoma. N Engl J Med 1978; 299: 1449-53.
17. Aviles A, Diaz-Maqueo JC, Garcia EL et al. Maintenance therapy with interferon-α2b in patients with diffuse large-cell lymphoma. Invest New Drugs 1992; 10: 351-5.
18. Bosley A, Radford J, Salles G et al. Interferon-α2b versus no treatment after intensive therapy and autologous stem-cell transplantation for relapsing lymphoma. Preliminary results of an international randomized study on 199 patients. Blood 1999; 94: 168a.